A RANDOMIZED CLINICAL TRIAL REGARDING COMPARATIVE EFFICACY OF QUININE AND ARTESUNATE IN THE TREATMENT OF SEVERE MALARIA AMONG CHILDREN OF TRIPURA: A NORTH-EASTERN STATE OF INDIA
Abstract
Background: Severe malaria is a medical emergency with high mortality in children. Recently, artesunate has replaced quinine as the first-line drug for severe malaria. Present study was undertaken to compare efficacy of quinine and artesunate in the treatment of severe malaria in children. Methods: A randomized clinical trial was conducted among children aged up to 12 years, admitted in the medical college hospital with clinical features of severe malaria (WHO criteria). All the children admitted in Paediatrics ward were diagnosed as Malaria by slide method and QBC Assay and after satisfying WHO criteria for severe malaria. Finally, 60 children were included in the study (30 in the quinine group and 30 in the artesunate group). Results: 60% children were aged 5 years or less and 40% children aged more than 5 years to 12 yrs. 90% children were afebrile within 48 hours after treated with artesunate as compared to 70% after treated with quinine. 90.33% children had parasites cleared within 48% hours with artesunate compared to 73.33% with quinine. 83.33% children were fully conscious within 24 hours in artesunate group compared to 33.33% with quinine for the same duration.Hypoglycaemia, nausea and vomiting (20% each) were the most common toxicities reported with quinine. 10% children complained of tinnitus. Neurotoxicity was reported in 6.66% children in both groups. Except 2 cases of neurotoxicity no other adverse reaction was reported with artesunate.There were 3 deaths (10%) in quinine arm, all death occurred after 48 hours of treatment, compared to 2 deaths (6.66%) in artesunate arm, all death within 24 hours of admission. Overall mortality was 8.33%.Conclusion: Artesunate is more effective than quinine in the treatment of severe malaria among children.
Keywords
Full Text:
PDFReferences
Govt. of India. NVBDCP. Strategic Action Plan for Malaria Control in India 2007-2012. New Delhi: Ministry of health and Family welfare; 2007.
WHO. World Malaria Report 2013. Geneva; WHO. 2013.
Nizamuddin M, Kogan F, Dhiman R, Guo W, Roytman L.Modelling and forecasting malaria in Tripura, India using NOAA/AVHRR‐Based Vegetation Health Indices. International Journal of Remote Sensing Applications. 2013; 3(3): 108-116.
Mohapatra PK, Prakash A, Bhattacharyya DR, Mahanta J. Malaria situation in North Eastern region of India. ICMR bulletin 1998. 28(3): 21-30.
Dua VK , Sharma SK , Srivastava A , Sharma VP . Bioenvironmental control of industrial malaria at Bharat Heavy Electricals Ltd., Hardwar, India-results of a nine-year study (1987-95).Journal of the American Mosquito Control Association. 1997; 13(3):278-285.
WHO: Guidelines for the treatment of malaria, 2nd edition- Rev.1. In. Geneva: World Health Organization; 2011.
AlKadi HO. Anti malarial drug toxicity: a review. Chemotherapy. 2007; 53(6): 385-391.
Okitolonda W, Delacollette C, Malengreau M, Henquin JC. High incidence of hypoglycaemia in African patients treated with intravenous quinine for severe malaria. Br Med J (Clin Res Ed). 1987; 295: 716–718.
White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Krishna S. et al. Severe hypoglycemia and hyper insulinemia in Falciparum Malaria. N Engl J Med. 1983; 309: 61-66.
Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, Vanijanonta S, Angus BJ, White NJ. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. The American Journal of Tropical Medicine and Hygiene. 1998; 59 (4): 519 – 522.
Nontprasert A , Pukrittayakamee S , Nosten-Bertrand M , Vanijanonta S , White NJ. Studies of the neurotoxicity of oral artemisinin derivatives in mice.The American Journal of Tropical Medicine and Hygiene. 2000; 62(3): 409-412
Nontprasert A, Pukrittayakamee S, Prakongpan S, Supanaranond W, Looareesuwan S, White NJ. Assessment of the neurotoxicity of oral dihydroartemisinin in mice.Transactions of The Royal Society of Tropical Medicine and Hygiene. 2002; 96 (1): 99–101.
Kissinger E, Hien TT, Hung NT, Nam ND, Tuyen NL, Dinh BV et al. Clinical and neuro physiological study of the effects of multiple doses of artemisinin on brain stem function in Vietnameses patients. The American Journal of Tropical Medicine and Hygiene. 2000; 62(1-2): 48-55.
Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Medicine Tropicale: revue du Corps de santé colonial. 1998; 58(3suppl): 50-53.
Dondorp A, Nosten F, Stepniewska DN, White NJ. For the South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005; 366: 717-25
Mohanty AK, Rath BK, Mohanty R, Samal AK, Mishra K. Randomized control trial of quinine and artesunate in complicated malaria. Indian Journal of Pediatrics. 2004; 71(4): 2915.
Cox XT, Bethell DB, Pham TP, Ta TT, Tran TN, Nguyen TT et al. Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1997; 91(3): 335-42.
Eltahir HG, Omer AA, Mohamed AA, Adam I. Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010; 104(10): 684-6.
Rolling T, Wichmann D, Schmiedel S, Burchard GD, Lluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focusing on delayed haemolysis. Malar J. 2013; 12: 241.
Dondorp A, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhgaganlal KD et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010; 376(9753): 1647-1657.
Refbacks
- There are currently no refbacks.